Physician profile
Hussein Elsemesmani
NPI 1821609108
$1,029.87
in general payments reported to CMS, 2019-2025
10 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $165 · 2024: $353 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.94 |
| Education | $159.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $211.67 | 2024-2025 | Impella |
| Pfizer INC. | $208.42 | 2024-2025 | |
| Abbott Laboratories | $167.72 | 2023-2025 | Ensite, Perclose Prostyle |
| Boston Scientific Corporation | $156.07 | 2023-2025 | General - Balloon Catheters, Ekosonic |
| Stryker Corporation | $147.42 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.76 | 2024-2025 | Lifevest |
| Medtronic, INC. | $30.32 | 2025 | Harmony |
| E.R. Squibb & Sons, L.L.C. | $27.50 | 2025 | Camzyos |
| Cardiva Medical, INC. | $26.60 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kestra Medical Technology Services, INC. | $22.39 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Elsemesmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.